Lonza Group (OTCMKTS:LZAGY) Raised to Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Lonza Group (OTCMKTS:LZAGY) from a neutral rating to a buy rating in a research note published on Tuesday, The Fly reports.

Several other research analysts also recently issued reports on LZAGY. Deutsche Bank Aktiengesellschaft restated a buy rating on shares of Lonza Group in a report on Tuesday, February 16th. William Blair restated an outperform rating on shares of Lonza Group in a research report on Thursday, February 11th. Morgan Stanley reiterated an overweight rating on shares of Lonza Group in a research report on Tuesday, May 11th. Zacks Investment Research lowered shares of Lonza Group from a buy rating to a hold rating in a report on Wednesday, April 28th. Finally, JPMorgan Chase & Co. upgraded shares of Lonza Group from a neutral rating to an overweight rating in a report on Tuesday, February 23rd. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $68.00.

Shares of LZAGY opened at $73.09 on Tuesday. The company has a market cap of $54.43 billion, a P/E ratio of 56.22 and a beta of 0.63. Lonza Group has a one year low of $48.40 and a one year high of $73.11. The stock has a fifty day moving average price of $62.59.

The firm also recently announced an annual dividend, which was paid on Thursday, May 27th. Investors of record on Tuesday, May 11th were issued a dividend of $0.094 per share. This represents a yield of 0.15%. The ex-dividend date was Monday, May 10th. Lonza Group’s payout ratio is 6.92%.

About Lonza Group

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications.

Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?

The Fly logo

Analyst Recommendations for Lonza Group (OTCMKTS:LZAGY)

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.